A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL).
Indolent Non-follicular|Non-Hodgkin's Lymphoma
DRUG: Bendamustine
Complete remission rate (CR), Evaluated at the end of treatment, 5 months
Safety analysis, Evaluated during and at the end of treatment. Percentage of patients with adverse, hematological and non-hematological toxic events, 5 months|Overall response rate (ORR), Evaluated at the end of treatment. Complete plus partial remission., 5 months|Overall survival (OS), Dead for any causes after diagnosis. Evaluated by means of Kaplan-Meier method., at 2 years|Progression free survival (PFS), Progression, relapse or dead for any causes after diagnosis. Evaluated by means of Kaplan-Meier method., at 2 years|Disease free survival (PFS), Relapse or dead for any causes from the end of treatment, for patients in CR after B+R. Evaluated by means of Kaplan-Meier method., at 2 years
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL).

The study includes and induction phase and a consolidation phase.